Hiroshi Yamamoto
Angel Investor @ ONO Pharmaceutical
Osaka, Japan
Hiroshi Yamamoto is a seed investor at ONO Pharmaceutical in Osaka focused on Medical and Robotics. Hiroshi Yamamoto - CEO @ Smaregi
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Hiroshi Yamamoto invests in
Stages Hiroshi Yamamoto invests in
Countries Hiroshi Yamamoto invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Robotics 1 (33%)
- Aerospace 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
Stage
- Seed 1 (33%)
- Series B 1 (33%)
- Series D 1 (33%)
Country
- Japan 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Interstellar Technologies is a rocket development, manufacturing and launch service. | $29.6M / Series D / Jan 16, 2023 | ||
| Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $20M / Seed / Mar 17, 2021 | ||
| Interstellar Technologies is a rocket development, manufacturing and launch service. | $170.1M / Series B / Jul 29, 2019 |
Co-Investors
About ONO Pharmaceutical
ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive.The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicateditself to developing innovative and breakthrough pharmaceutical products.
ONO Pharmaceutical Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gyo Sagara
Chief Executive Officer
|
|||
|
Hiroshi Ichikawa
Executive Director, Sales and Marketing
|
|||
|
Yukio Tani
Director, Corporate Communications
|
|||
|
Ichibei Ono
Founder
|
|||
|
Toichi Takino
Senior Executive Director, Discovery & Research
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hiroshi Yamamoto invest in?
Hiroshi Yamamoto invests primarily in Medical, Robotics and Aerospace startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hiroshi Yamamoto?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Hiroshi Yamamoto last invest?
The most recent investment recorded for Hiroshi Yamamoto closed in Jan 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
